Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ON123300 是一种可透过血脑屏障的多激酶抑制剂,作用于 CDK4、CDK6、Ark5、PDGFRβ、FGFR1、RET 和 Fyn,IC50值为3.9、9.82、5、26、26、9.2和11 nM。它在脑肿瘤中抑制 Akt 磷酸化及激活 Erk。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 343 | 现货 | ||
2 mg | ¥ 496 | 现货 | ||
5 mg | ¥ 818 | 现货 | ||
10 mg | ¥ 1,330 | 现货 | ||
25 mg | ¥ 2,290 | 现货 | ||
50 mg | ¥ 3,480 | 现货 | ||
100 mg | ¥ 5,220 | 现货 | ||
500 mg | ¥ 10,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 883 | 现货 |
产品描述 | ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM). |
靶点活性 | Ark5:5nM, PDGFRβ:26nM, Fyn:11 nM, CDK4:3.9nM, FGFR1:26nM, RET:9.2nM |
激酶实验 | CDK1 kinase activity is tested by the CDK1/cyclin B complex purified from baculovirus to phosphorylate a biotinylated peptide substrate containing the consensus phosphorylation site for histone H1, which is phosphorylated in vivo by CDK1. Inhibition of CDK1 activity is measured by observing a decreased amount of 33P-γ-ATP incorporation into the immobilized substrate in streptavidin-coated 96-well scintillating microplates. CDK1 enzyme is diluted in 50 mM Tris-HCl (pH 8), 10 mM MgCl2, 0.1 mM Na3VO4, 1 mM DTT, 1% DMSO, 0.25 μM peptide, 0.1 μCi per well 33P-γ-ATP, and 5 μM ATP in the presence or absence of various concentrations of JNJ-7706621 and incubated at 30 °C for 1 hour. The reaction is terminated by washing with PBS containing 100 mM EDTA and plates are counted in a scintillation counter. IC50 is determined by Linear regression analysis of the percent inhibition by JNJ-7706621. |
分子量 | 429.52 |
分子式 | C24H27N7O |
CAS No. | 1357470-29-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 28 mg/mL (65.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3282 mL | 11.6409 mL | 23.2818 mL | 58.2045 mL |
5 mM | 0.4656 mL | 2.3282 mL | 4.6564 mL | 11.6409 mL | |
10 mM | 0.2328 mL | 1.1641 mL | 2.3282 mL | 5.8205 mL | |
20 mM | 0.1164 mL | 0.582 mL | 1.1641 mL | 2.9102 mL | |
50 mM | 0.0466 mL | 0.2328 mL | 0.4656 mL | 1.1641 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ON123300 1357470-29-1 Angiogenesis Apoptosis Cell Cycle/Checkpoint Chromatin/Epigenetic JAK/STAT signaling PI3K/Akt/mTOR signaling Stem Cells Tyrosine Kinase/Adaptors FGFR c-RET JAK CDK PDGFR Src AMPK Platelet-derived growth factor receptor AMP-activated protein kinase FGFR1 kinase brain Ark5 U87 inhibit multi RET tumor Inhibitor glioma Cyclin dependent kinase CDK4 FYN RTK penetration PDGFRβ ON-123300 CDK6 ON 123300 inhibitor